Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalyn Pharma Inc.AVLN · Entity 4662 | Director · Chief Executive Officer | April 29, 2026 | May 01, 2026 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 25, 2022 | May 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalyn Pharma Inc.
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-28 | Direct | 501,033 |
Reported balance
After 2026-04-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-29 · Grant · Acquired 501,033 · Balance 501,033 F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Rani Therapeutics Holdings, Inc.
Report date May 25, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.89 · Expires 2032-05-24 | Direct | 22,240 |
Reported balance
After 2022-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-25 · Grant · Acquired 22,240 · Balance 22,240 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed May 1, 2026 22:25 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | GrantStock Option (Right to Buy) · Derivative | 501,033 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-201856 · ownership.xml · derivative · entry 1 Baranowski Lyn · CIK 0001893640 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,033 Underlying: Common Stock · 501,033 shares Expires 2036-04-28 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 12:30 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 22,240 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-22-019854 · doc4.xml · derivative · entry 1 Baranowski Lyn · CIK 0001893640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,240 Underlying: Class A Common Stock · 22,240 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 23:32 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 31,695 | $0.00 Strike: $26.78 | $0.00 |
DisclosureSEC source: 0001209191-21-064339 · doc4.xml · derivative · entry 1 Baranowski Lyn · CIK 0001893640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,695 Underlying: Class A Common Stock · 31,695 shares Expires 2031-11-09 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on November 10, 2022; and 1/36th of the shares subject to the option vest monthly thereafter over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.